Press release

Prime Therapeutics joins ICER as flagship member

Prime joins leaders from almost 20 organizations to develop innovative approaches to drug evaluation, pricing, coverage and payment.

ST. PAUL, MINN. – Sept. 23, 2016 – Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM), has joined the Institute for Clinical and Economic Review (ICER) membership program as a flagship member.

Through the ICER membership, Prime will join an influential group of leaders from almost 20 organizations including insurers, pharmacy benefit managers, life science companies and pharmaceutical manufacturers to develop innovative approaches to drug evaluation, pricing, coverage and payment.

As a flagship member, Prime will provide important insight on issues related to the evaluation of evidence on clinical effectiveness and value of new drugs, and on how that evidence can be used to improve patient outcomes while controlling costs. Member organizations work to improve understanding across stakeholders, providing an analysis of the policy landscape and laying the groundwork for collaborative efforts. Past topics have addressed indication-specific pricing, the interpretation of surrogate outcome measures in cancer clinical trials, and the design and interpretation of indirect treatment comparison analyses. A future summit will focus on evaluating the evidence and designing payment options for curative gene therapies.

“At Prime, we’re serious about identifying the value drugs bring,” said Prime’s Chief Medical Officer Dr. Jon Gavras (pictured right). “Prime’s ICER membership puts us at the table with other leaders who are working together to develop the tools and insights that will drive the value agenda forward. We look forward to contributing to those conversations, and we feel they will ultimately help us bring medicines to our members that provide the best balance of efficacy, safety and cost.”

Gavras will join leaders from ICER flagship members and other policy experts on ICER’s stakeholder advisory board. This board provides input on ICER’s membership activities and other opportunities for collaboration, but it does not exercise influence over ICER’s selection of specific topics for review nor on the conduct of ICER reviews. 

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves just over 22 million people. It is collectively owned by 14 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.  

Follow @Prime_PBM on Twitter.

Sign-up for regular news announcements from Prime Therapeutics.


Denise Lecher
Prime Therapeutics
Manager, Corporate Communication